TAMPA, Fla., Sep 12, 2006 (BUSINESS WIRE) -- Nanobac Pharmaceuticals, Inc. (OTCBB: NNBP) ("Nanobac" or "the Company") today announced the release of an analytical profile on the Company, by respected micro-cap analyst Mr. Paul Silver, Director of Research for Wall Street Resources, Inc., which contains a short-term target value for NNBP of $0.91 per share.
The free report is available at: wallstreetresources.net.
The 31-page report includes detailed information on the Company's business model, products, industry, valuation, management and risks. Wall Street Resources, Inc. is a professional research and consulting firm with over 10 years of experience providing analysis for emerging growth companies and information to the investment community.
¶ We believe that calcification is a significant feature in most diseases that are leading causes of death, including heart disease. Calcification is shown in numerous studies to block circulation, cause inflammation and cell disruption, and is a possible sign of cancers. We have decided to have a sharpened focus on drug therapy based on findings by Nanobac scientists that certain drugs, when combined, are effective at halting the calcification process. Some of these drug combinations have not been tested in animals or humans. However, the Company has an advantage in that each of these drugs on its own has an FDA-approved record of being safe, therefore regulatory hurdles are significantly lower in every national jurisdiction.
¶ Our plan is to focus on the following priorities over the next 12-18 months:
>> Therapy - We are entering into agreements to test our proprietary drug combinations to treat stone-forming diseases, with a preliminary focus on prostatitis, which affects millions of men and currently is largely untreatable. We will also conduct tests with other stone forming diseases such as gallstones and kidney stones.
>> Infection - The gold standard for proving that something is infectious is Koch's postulates. We intend to validate earlier findings on Koch's postulates with calcifying nanoparticles in laboratory animals, including testing whether the infection can be prevented or treated with a proprietary drug combination.
>> Characterization - We have preliminary photographic and biochemical evidence that calcifying nanoparticles self-replicate in non-precipitating conditions, suggesting further that they have the ability to be infectious. We have designed an experiment with NASA to demonstrate this via time-lapse photography, using new microscopic technology developed in 2005.
>> Thrombosis - Thrombosis is the cause of death in most hemodialysis patients. We intend to validate findings that calcifying nanoparticles discovered in human blood provoke thrombosis and might be preventable.
>> Diagnostics - We believe that our proprietary Elisa antibody test uniquely recognizes calcifying nanoparticles known as nanobacteria, and plan to further validate the functionality of this diagnostic test.
¶ Nanobac Pharmaceuticals, Inc. is headquartered in Tampa, Florida. Web site nanobac.com.
¶ Patent details here: tinyurl.com US Patent 6,706,290 Claim 13: A method for inhibiting or treating the development of calcifications in vivo in a patient in need of such inhibition or treatment, comprising administering an antibiotic to the patient in an amount sufficient to inhibit the growth of nanobacteria; wherein the antibiotic is selected from the group consisting of .beta.-lactam antibiotics, aminoglycoside antibiotics, tetracycline antibiotics, trimethoprim antibiotics, nitrofurantoin antibiotics and pharmaceutically acceptable salts thereof, and mixtures thereof. tinyurl.com
Shares Outstanding: 193.51M
Float: 83.77M |
